IN8bio reports Q1 2024 net loss $8.6M, cash $13.0M; first patient dosed in INB-400 Phase 2

IN8BIO, INC.

2024-Q1 EPS reported -$0.20

Q1 net loss $8.6M ($0.20/sh) vs $7.5M ($0.30/sh) in Q1 2023; R&D $4.9M, G&A $3.7M.
Cash $13.0M at March 31, 2024, down from $21.3M at December 31, 2023.
First patient dosed in Phase 2 autologous arm of INB-400 for newly diagnosed GBM.
Potential IND submission for INB-100 Phase 2 registrational trial in 2024 in AML/MDS.
Preclinical nsCAR data at AACR 2024 targeting CD33/CD123 for AML while sparing healthy cells.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.